Keywords: Amgen, Prolia, CSl Behring, Berinert, European approvals
EU approvals for Amgen’s osteo drug Prolia and CSL Behring HAE agent Berinert
Article | 28 May 2010
US biotechnology major Amgen got its first ever approval for Prolia (denosumab) from the European Commission, which granted marketing authorization ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
